Family of 2-year-old who died from reaction to ant bites sues hospital for ‘inexcusable' treatment
Toddler Maya Getahun was playing in her front yard on October 7 last year when she was bitten by fire ants and began showing signs of an allergic reaction, according to the lawsuit filed last week.
Her parents, Bethelhem Getu Hundie and Getahun Birhanu, immediately took her to Piedmont Eastside Medical Center in Snellville, Georgia. By the time she arrived, Maya had a rash while experiencing wheezing and labored breathing.
The lawsuit alleges healthcare staff then waited more than 20 minutes to give Maya epinephrine, the medication in an Epi-Pen used to treat allergic reactions.
Hospital staff then decided to intubate Maya when her blood oxygen saturation levels were at 97 percent, the lawsuit alleges.
Dr. Richisa Salazar, who is named as a defendant, then administered drugs that paralyzed Maya to prepare her for the intubation. After administering the drugs, however, Salazar realized the hospital didn't have the proper child-sized equipment to perform the intubation, the lawsuit alleges.
Maya died soon afterward. Now, her parents and their attorneys say her death was '100% preventable.'
'If only the hospital staff had promptly administered epinephrine, Maya would still be alive,' Lloyd Bell, an attorney representing Maya's family, said in a statement. 'If only the hospital had the proper equipment to intubate a child, Maya would still be alive.'
'The failures at Piedmont Eastside, from delayed treatment to inadequate resources, were not only negligent but inexcusable,' he added.
Bell says Salazar has been named in two other medical malpractice cases prosecuted by his firm alone.
Maya's family is now seeking a jury trial and damages related to their pain and suffering and the cost of her funeral.
'This case is about accountability,' Bell said. 'No family should ever experience the heartbreak of losing a child due to a hospital's lack of preparation, especially for something as foreseeable as an allergic reaction. Our goal is to obtain full justice for Maya and help ensure that what happened to Maya never happens to another child.'
The Independent has contacted Piedmont Eastside Medical Center and Salazar for comment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
25-07-2025
- UPI
Wisconsin Lt. Gov. Sara Rodriguez launches gubernatorial bid
Wisconsin Lt. Gov. Sara Rodriguez is running for governor, the former emergency room nurse confirmed Friday. Photo courtesy of Governor of Wisconsin's office July 25 (UPI) -- Wisconsin Lt. Gov. Sara Rodriguez is running for governor, the former emergency room nurse confirmed Friday. "I'm used to being on my feet and getting right to the point, so let's go. First, I have an announcement. I'm running for governor," Rodriguez announced in a video released Friday, her 50th birthday. Rodriguez joins the Democratic primary field to replace Gov. Tony Evers, D-Wis. Evers, 73, announced in a video Thursday he would not seek re-election in November when he will turn 74. Evers has been the Governor of Wisconsin for six years and in public service for 50 years. Rodriguez is the first big name to enter the race to replace Evers. Milwaukee County Executive David Crowley confirmed Thursday to Spectrum News 1 Wisconsin that he plans to run. Former Wisconsin Lt. Gov. Mandela Barnes posted a photo of himself with Evers on X Thursday, thanking him for his service. Barnes served as lieutenant governor during Evers' first term and has hinted at a run for the office. Rodriguez previously worked in the emergency department of Baltimore's Mercy Medical Center. She later took a job at the U.S. Centers for Disease Control and Prevention between 2004 and 2006 before returning to Wisconsin. Increasing salaries for public teachers and expanding Medicaid access are among the promises Rodriguez makes in the video. "Look, we've got a real shot at flipping the state Legislature and with a Democratic governor, we can finally expand Medicaid and boost our healthcare workforce," Rodriguez says in the video, that also touches on her family's working-class roots in Wisconsin. "With a Democratic governor, we can finally expand Medicaid and boost our healthcare workforce, strengthen our farms, unions, and small businesses, fund our public schools and give teachers the raise they've earned. That's the right path."
Business Wire
22-07-2025
- Business Wire
Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS), through the MolDX program, has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. A 'gapfill' payment rate means that pricing is determined by each Medicare contractor, including MolDX, based on cost data from Cardio Diagnostics. These preliminary payment rates, proposed as part of the calendar year 2025 gapfill pricing process, are expected to be finalized later this year and will be effective for claims with dates of service on or after January 1, 2025. The proposed rates represent a significant positive development in the Company's efforts to expand access to its advanced cardiovascular testing for Medicare beneficiaries. 'We view this as a critical step toward expanding timely access and improving care for Medicare patients' said Meesha Dogan, PhD., CEO and Co-Founder of Cardio Diagnostics. 'Many Medicare beneficiaries, who are at elevated risk for coronary heart disease, go undetected and undertreated, often resulting in avoidable heart attacks, hospitalizations, and poor outcomes.' Cardio Diagnostics clarified during a recent meeting with MolDX that initial public documentation had inadvertently transposed the pricing between the two tests, and MolDX confirmed the correct association of the proposed payment rates to their respective tests. Addressing the Leading Cause of Death Cardiovascular disease remains the leading cause of death in the United States, particularly among Americans aged 65 and older. In 2022 alone, over 700,000 Americans died from heart disease, with coronary heart disease (CHD) accounting for more than 370,000 deaths. PrecisionCHD™ is a groundbreaking AI-powered test designed to aid in the diagnosis of CHD by analyzing both genetic and epigenetic markers. Meanwhile, Epi+Gen CHD™ provides insight into a patient's three-year risk for a CHD event, such as a heart attack. Both tests are performed from a simple blood draw, enabling scalable, accessible, and non-invasive cardiovascular assessment. Both tests received dedicated CPT Proprietary Laboratory Analysis (PLA) codes from the American Medical Association, 0439U for Epi+Gen CHD and 0440U for PrecisionCHD, that were effective on April 1, 2024. About Cardio Diagnostics Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ('Core Technology') for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit Forward-Looking Statements Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2024, under the heading 'Risk Factors' in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
Medscape
17-07-2025
- Medscape
Rapid Review: Exocrine Pancreatic Insufficiency (EPI)
While historically underdiagnosed, increased awareness and improved diagnostic strategies for exocrine pancreatic insufficiency (EPI) have helped identify patients earlier, thus facilitating more effective management. However, despite advances in treatment modalities, patient outcomes vary considerably due to differences in individual physiology, adherence to treatment regimens, and concurrent health issues. Efforts to address these disparities focus increasingly on personalized medicine, emphasizing the integration of tailored nutritional strategies, patient education, and multidisciplinary care teams to improve patient outcomes comprehensively. Recent guidelines advocate for the prompt initiation of PERT as soon as EPI is diagnosed. Additionally, a multidisciplinary evaluation to assess further nutritional needs and coordination with endocrinologists for the evaluation and treatment of diabetes is also warranted. Untreated EPI can impair growth in pediatric patients, and is associated with a number of clinical symptoms including gastrointestinal effects, osteoporosis, sarcopenia, coagulopathy, neuropathy, and other sequelae related to nutrient deficiency. Although other tests can help in certain cases, EPI can be sufficiently diagnosed with a validated pancreatic function test, and awaiting further confirmatory information such as severe clinical symptoms, positive imaging findings, or documented nutritional deficiencies is not necessary. Learn more about management approaches for EPI. Digestion of fat is a central function of the pancreas, with dysfunction causing deficiency in fat soluble essential vitamins. Although the American Gastroenterological Association (AGA) guidelines recommend a low-to-moderate-fat diet for patients with EPI, they specifically recommend against a very-low fat diet as this can exacerbate deficiencies. Further, meals should be more frequent and smaller, and vitamin and mineral deficiencies should be screened for at diagnosis and annually thereafter. Learn more about diet in EPI. Although fecal fat testing is considered the gold-standard for assessing fecal fat malabsorption, which is a measure of pancreatic dysfunction, it has low specificity for EPI since other diseases can present with steatorrhea. The AGA notes that fecal fat testing is 'rarely needed', it is burdensome (requires a 72 hour stool collection), and can only be done when the patient is on a high-fat diet. Additionally, fecal fat tests are known to be susceptible to false positive results in patients with diarrhea, which is a common symptom of EPI. The AGA recommends fecal elastase as the best test for initial screening, although fecal fat may be useful in cases with inconclusive clinical features and imaging. Learn more about pancreatic function tests. The AGA Clinical Practice Update emphasizes that while cross-sectional imaging — such as CT, MRI, and endoscopic ultrasound — cannot directly diagnose EPI, it plays an essential role in identifying benign and malignant pancreatic diseases that may underlie or contribute to exocrine insufficiency. Imaging can reveal features like advanced calcific chronic pancreatitis, ductal changes, or significant pancreatic atrophy, which correlate with the presence of EPI. However, moderate changes in imaging do not reliably correlate with EPI, and normal imaging is associated with its absence. Although advanced tools like secretin-enhanced MRCP or elastography show promise, current imaging lacks sufficient accuracy to predict EPI on its own. Therefore, imaging should be viewed as a complementary tool in the diagnostic process, providing context about pancreatic structure rather than functional status. For dosing of PERT, the AGA has specific recommendations dependent on fat content of meals and current symptom profile, not imaging findings. Learn more about the multidisciplinary workup for patients with EPI. The latest AGA guidelines emphasize the importance of regular and comprehensive monitoring of nutritional status in all patients with EPI, including regular DEXA scans every 1-2 years. Additionally, baseline and periodic assessment of anthropometric indicators, biochemical markers, and clinical evaluation should be established. DEXA scanning can help to detect sarcopenia, which is possible even in patients with obesity. It can be caused by the nutritional deficits seen in patients with EPI and is associated with increased adverse outcomes and physical disability. The AGA also notes that other muscle mass and function tests can be considered as well. Learn more about the management of patients with EPI.
